Angiotensin Therapeutics
Angiotensin Therapeutics, a startup based on Prof. Daniel Batlle's research, is developing a best-in-class ACE2 variant to create breakthrough therapies for COVID-19 and the treatment of kidney disease.
Angiotensin Therapeutics, a startup based on Prof. Daniel Batlle's research, is developing a best-in-class ACE2 variant to create breakthrough therapies for COVID-19 and the treatment of kidney disease.